Study Evaluating Safety and Efficacy of CAR-T Cells Targeting CD123 in Patients With Acute Myelocytic Leukemia
Conditions
- Acute Myelocytic Leukemia
Interventions
- BIOLOGICAL: CD123 CAR-T cells
Sponsor
Hebei Senlang Biotechnology Inc., Ltd.
Collaborators